This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sangamo BioSciences' CEO Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Sangamo BioSciences (SGMO)

Presentation at Bank of America Merrill Lynch 2012 Health Care Conference

May 16, 2012 5:20 p.m. ET


Edward Lanphier - President and CEO


Rachel McMinn - Bank of America Merrill Lynch


Rachel McMinn - Bank of America Merrill Lynch

My name’s Rachel McMinn. I’m one of the biotech analysts here at Bank of America Merrill Lynch. It’s my pleasure to introduce our next speaker. The company is Sangamo BioSciences, and our speaker is President and CEO Ed Lanphier. Thanks so much.

Edward Lanphier

Thank you Rachel, and thanks for including us in this year’s conference. It’s a pleasure to be here. My presentation will continue forward looking statements, and I’d refer you to our forms 10-K, 10-Q, filed with the SEC.

Starting at 30,000 feet, the single fact that differentiates Sangamo from every company at this meeting, every company in biotech, is our core technology, our ability to engineer a naturally occurring class of proteins that bind DNA. And these are called zinc finger proteins.

They’re actually the most common, the most abundant, class of DNA binding proteins found on our planet, and the reason being is evolution found these to be very engineerable, very manipulable, in that they can bind to three sequences of DNA, three base pairs of DNA, and then linking these together kind of like Legos, could build proteins that could recognize longer and more specific sequences of DNA.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs